Anti-Ro52 autoantibodies from patients with Sjögren's syndrome inhibit the Ro52 E3 ligase activity by blocking the E3/E2 interface
- PMID: 21862588
- PMCID: PMC3196112
- DOI: 10.1074/jbc.M111.241786
Anti-Ro52 autoantibodies from patients with Sjögren's syndrome inhibit the Ro52 E3 ligase activity by blocking the E3/E2 interface
Abstract
Ro52 (TRIM21) is an E3 ligase of the tripartite motif family that negatively regulates proinflammatory cytokine production by ubiquitinating transcription factors of the interferon regulatory factor family. Autoantibodies to Ro52 are present in patients with lupus and Sjögren's syndrome, but it is not known if these autoantibodies affect the function of Ro52. To address this question, the requirements for Ro52 E3 ligase activity were first analyzed in detail. Scanning a panel of E2 ubiquitin-conjugating enzymes, we found that UBE2D1-4 and UBE2E1-2 supported the E3 ligase activity of Ro52 and that the E3 ligase activity of Ro52 was dependent on its RING domain. We also found that the N-terminal extensions in the class III E2 enzymes affected their interaction with Ro52. Although the N-terminal extension in UBE2E3 made this E2 enzyme unable to function together with Ro52, the N-terminal extensions in UBE2E1 and UBE2E2 allowed for a functional interaction with Ro52. Anti-Ro52-positive patient sera and affinity-purified anti-RING domain autoantibodies inhibited the E3 activity of Ro52 in ubiquitination assays. Using NMR, limited proteolysis, ELISA, and Ro52 mutants, we mapped the interactions between Ro52, UBE2E1, and anti-Ro52 autoantibodies. We found that anti-Ro52 autoantibodies inhibited the E3 ligase activity of Ro52 by sterically blocking the E2/E3 interaction between Ro52 and UBE2E1. Our data suggest that anti-Ro52 autoantibodies binding the RING domain of Ro52 may be actively involved in the pathogenesis of rheumatic autoimmune disease by inhibiting Ro52-mediated ubiquitination.
Figures
![FIGURE 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3196112/bin/zbc0471182570001.gif)
![FIGURE 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3196112/bin/zbc0471182570002.gif)
![FIGURE 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3196112/bin/zbc0471182570003.gif)
![FIGURE 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3196112/bin/zbc0471182570004.gif)
![FIGURE 5.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3196112/bin/zbc0471182570005.gif)
![FIGURE 6.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3196112/bin/zbc0471182570006.gif)
![FIGURE 7.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3196112/bin/zbc0471182570007.gif)
![FIGURE 8.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3196112/bin/zbc0471182570008.gif)
Similar articles
-
The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death.J Immunol. 2006 May 15;176(10):6277-85. doi: 10.4049/jimmunol.176.10.6277. J Immunol. 2006. PMID: 16670339
-
Autoantigen Ro52 is an E3 ubiquitin ligase.Biochem Biophys Res Commun. 2006 Jan 6;339(1):415-21. doi: 10.1016/j.bbrc.2005.11.029. Epub 2005 Nov 14. Biochem Biophys Res Commun. 2006. PMID: 16297862
-
E3 ubiquitin-protein ligase TRIM21-mediated lysine capture by UBE2E1 reveals substrate-targeting mode of a ubiquitin-conjugating E2.J Biol Chem. 2019 Jul 26;294(30):11404-11419. doi: 10.1074/jbc.RA119.008485. Epub 2019 Jun 3. J Biol Chem. 2019. PMID: 31160341 Free PMC article.
-
The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review.J Autoimmun. 2012 Aug;39(1-2):77-82. doi: 10.1016/j.jaut.2012.01.014. Epub 2012 Mar 7. J Autoimmun. 2012. PMID: 22402340 Review.
-
Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis.Clin Rev Allergy Immunol. 2022 Oct;63(2):178-193. doi: 10.1007/s12016-021-08911-z. Epub 2022 Jan 18. Clin Rev Allergy Immunol. 2022. PMID: 35040083 Review.
Cited by
-
Roles of TRIM21/Ro52 in connective tissue disease-associated interstitial lung diseases.Front Immunol. 2024 Aug 6;15:1435525. doi: 10.3389/fimmu.2024.1435525. eCollection 2024. Front Immunol. 2024. PMID: 39165359 Free PMC article. Review.
-
Clinical features of patients with systemic sclerosis positive for anti-SS-A antibody: a cohort study of 156 patients.Arthritis Res Ther. 2024 May 3;26(1):93. doi: 10.1186/s13075-024-03325-6. Arthritis Res Ther. 2024. PMID: 38702799 Free PMC article.
-
14-3-3η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome.Arch Iran Med. 2023 Oct 1;26(10):582-591. doi: 10.34172/aim.2023.85. Arch Iran Med. 2023. PMID: 38310415 Free PMC article.
-
Dissociating Autoantibody Responses against Ro52 Antigen in Patients with Anti-Synthetase or Anti-MDA5 Antibodies.Diagnostics (Basel). 2023 Dec 8;13(24):3621. doi: 10.3390/diagnostics13243621. Diagnostics (Basel). 2023. PMID: 38132205 Free PMC article.
-
Autoimmune diseases: targets, biology, and drug discovery.Acta Pharmacol Sin. 2024 Apr;45(4):674-685. doi: 10.1038/s41401-023-01207-2. Epub 2023 Dec 14. Acta Pharmacol Sin. 2024. PMID: 38097717 Review.
References
-
- Strandberg L., Ambrosi A., Espinosa A., Ottosson L., Eloranta M. L., Zhou W., Elfving A., Greenfield E., Kuchroo V. K., Wahren-Herlenius M. (2008) J. Clin. Immunol. 28, 220–231 - PubMed
-
- Wahren M., Tengnér P., Gunnarsson I., Lundberg I., Hedfors E., Ringertz N. R., Pettersson I. (1998) J. Autoimmun. 11, 29–38 - PubMed
-
- Borden K. L., Freemont P. S. (1996) Curr. Opin. Struct. Biol. 6, 395–401 - PubMed
-
- Borden K. L., Martin S. R., O'Reilly N. J., Lally J. M., Reddy B. A., Etkin L. D., Freemont P. S. (1993) FEBS Lett. 335, 255–260 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials